Clinical Cancer Research, Vol 3, Issue 9 1669-1673, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations

KE McKenzie, A Siva, S Maier, IB Runnebaum, R Seshadri and S Sukumar
Breast Cancer Program, Johns Hopkins Oncology Center, Baltimore, Maryland 21045, USA.

Seventy-five to 80% of breast cancers are negative for p53 gene mutations. We have investigated the possibility that altered WAF1 genes provide an alternative mode of cell cycle disruption in these tumors. DNA from a total of 85 primary breast tumors and cell lines from both the United States and Australia were examined for WAF1 and p53 mutations. With the exception of one primary tumor containing the polymorphic codon 31 (AGC-->AGA), no missense mutations in the WAF1 gene were found in 33 primary tumors or in the 19 cell lines from the United States. By contrast, 2 of 33 tumors from Australia contained tumor-specific missense mutations in the WAF1 gene, while an additional six cases contained the AGC-->AGA polymorphic 31st codon in the WAF1 gene. The p53 mutation frequency in the Australian cohort (18%) was found to be similar to that reported by us (Glebov et al., Cancer Res., 54: 3703-3709, 1994; Runnebaum et al., Proc. Natl. Acad. Sci. USA, 88: 10657-10661, 1991) in the tumors of United States patients (13%) with sporadic breast cancer. Thus, mutations in the WAF1 gene are rare in tumors with or without p53 mutations, suggesting that except in a minor population of breast cancer patients of Caucasian origin, cell cycle dysregulation by mutated p53 or WAF1 genes may not contribute to breast tumor initiation or progression.

This article has been cited by other articles:

				Y.-G. Xi, K.-Y. Ding, X.-L. Su, D.-F. Chen, W.-C. You, Y. Shen, and Y. Ke p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions Carcinogenesis, November 1, 2004; 25(11): 2201 - 2206. [Abstract] [Full Text] [PDF]

				V. Staalesen, B. Leirvaag, J. R. Lillehaug, and P. E. Lonning Genetic and Epigenetic Changes in p21 and p21B Do Not Correlate with Resistance to Doxorubicin or Mitomycin and 5-Fluorouracil in Locally Advanced Breast Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3438 - 3443. [Abstract] [Full Text] [PDF]

				B. L. Powell, I. L. van Staveren, P. Roosken, F. Grieu, E. M.J.J. Berns, and B. Iacopetta Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer Carcinogenesis, February 1, 2002; 23(2): 311 - 315. [Abstract] [Full Text] [PDF]

				C. Keshava, B. L. Frye, M. S. Wolff, E. C. McCanlies, and A. Weston Waf-1 (p21) and p53 Polymorphisms in Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 127 - 130. [Abstract] [Full Text]

				Y. Harima, K. Harima, S. Sawada, Y. Tanaka, S. Arita, and T. Ohnishi Loss of Heterozygosity on Chromosome 6p21.2 as a Potential Marker for Recurrence after Radiotherapy of Human Cervical Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1079 - 1085. [Abstract] [Full Text]